AstraZeneca: European Commission Approves Expanded Use Of Ultomiris For Children, Adolescents

AstraZeneca PLC (AZN.L) announced Ultomiris has been approved in the European Union for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria. The approval by the European Commission was based on interim results from the phase III clinical trial, the company said.

Ultomiris was previously approved in the EU for the treatment of adults with paroxysmal nocturnal haemoglobinuria and is also approved for the treatment of adults and children with atypical haemolytic uraemic syndrome.

Marc Dunoyer, CEO, Alexion, said: "Ultomiris has become the standard of care for the treatment of adults with PNH and we will make it available to this younger patient population as soon as possible."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple announced that Apple News will be extending its local news offering to three additional cities in the United States to offer local news experience to readers. The service will now be provided for Charlotte, Miami, and Washington, D.C. The local news experience for each city is curated by Apple News editors to provide coverage of topics of importance for local communities. Automaker General Motors Co. (GM) on Wednesday reported third-quarter net income attributable to shareholders of $2.42 billion or $1.62 per share, lower than $4.05 billion or $2.78 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $1.52 per share, compared... Boeing on Wednesday reported a loss for the first quarter that sharply narrowed from last year, reflecting an 8 percent increase in revenues on higher commercial airplanes and services volumes. However, core loss per share and quarterly revenues came in below analysts' expectations. Looking ahead, the airplane maker said supply chain capacity and global trade will be key drivers of the industry.
Follow RTT